Objective: To investigate whether the risk of incident cardiovascular disease (CVD) is increased in patients with prolactinoma.
period to high prolactin (PRL) exposure ranges between 0.5 and 12 years, 1 and macroadenomas, with the potential to cause various degrees of hypopituitarism, account for 19%-24% of the total cases and up to 75% of the male patients. 1, 2, 5 First-line treatment is dopamine agonists, with cabergoline achieving normal PRL in approximately 90% of microadenomas and 60%-90% of macroadenomas. In cases of resistance or intolerance to medical treatment, surgery combined or not with radiotherapy are further options, with various success rates and complications. [7] [8] [9] Apart from the impact on the hypothalamo-pituitary-gonadal axis, untreated hyperprolactinaemia has been associated with metabolic derangement and insulin resistance. [10] [11] [12] These observations are consistent with the sympatholytic effects on D2-dopamine receptors which are currently studied for the treatment of diabetes mellitus type 2. 13, 14 It has been also shown that patients with untreated newly diagnosed prolactinoma demonstrate a hypercoagulable state, reflected in elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, platelet count, fibrinogen, plasminogen activator inhibitor-1 (PAI-1), alongside reduced plasma tissue factor pathway inhibitor levels.
15
However, these reports were universally confirmed in the literature.
16
Adequately powered studies systematically assessing the risk of cardiovascular disease (CVD) in patients with prolactinoma (directly through the hyperprolactinaemia per se or indirectly through associated hypopituitarism) are not available. We, thus, for the first time, undertook a population-based, retrospective, open-cohort study aiming to clarify the long-term cardiovascular risk in these patients by comparing them to appropriately matched controls.
| MATERIALS AND METHODS

| Study design
This was a population-based, retrospective, open-cohort study in which patients with the diagnosis of prolactinoma were compared to age, sex, body mass index (BMI) and smoking status-matched controls who did not have this diagnosis.
| Source of data
Patient data were sourced from The Health Improvement Network database (THIN). THIN data are generated from longitudinal data documented in electronic medical records by General Practitioners during each episode of consultation using Read codes (a hierarchical coding system for structured storage of information). 
| Selection of the study population
The study cohort consisted of two subcohorts; the "exposed," including patients diagnosed with prolactinoma and the "nonexposed" one (controls, matched on a 5:1 ratio to each "exposed" subject) with no diagnosis of prolactinoma before or during the observation period.
The "exposure" was defined by a Read code specific for prolactinoma (detailed list of relevant Read codes are available in the Appendix S1).
Records of any dopamine agonist treatment (cabergoline, bromocriptine, quinagolide) were also collected. 
| Observation period
The study period was set from 1 January 1990 to 1 September 2015.
Each patient diagnosed with a prolactinoma was followed up from their index date (start of observation at the patient level) until the patient died, left the Practice, the Practice ceased data collection or a positive study outcome (cardiovascular event) was recorded. Patients with CVD recorded any time prior to the index date (at baseline) were excluded from the study (only incident CDV was considered). Observation period and study entry requirements were identical in the control cohort.
| Sensitivity and subgroup analyses
Given the observational nature of the evidence, sensitivity analyses were performed aiming to check whether a change in the initial assumptions could have an impact on the findings. Thus, an alternative definition of "exposure," namely a Read code specific for prolactinoma and a concurrent documented treatment with any dopamine agonist, was used in a sensitivity analysis to further consolidate the diagnosis of prolactinoma. Furthermore, a sensitivity analysis was also undertaken limiting to those patients with an incident diagnosis of prolactinoma (patients with a new diagnosis after joining Practice) and their respective controls aiming to diminish the bias associated with the inclusion of prevalent cases. Finally, as prolactinomas are diagnosed at an earlier age in women, 1,2 a subgroup analysis limiting to those female patients aged above 45 years and their respective controls was also undertaken to offset any bias related to the low risk for CVD in premenopausal women. 
| Statistical analyses
| RESULTS
| Baseline characteristics
A total of 2233 prevalent (diagnosed before the index date) and incident (diagnosed after the index date) patients with prolactinoma (1822 females and 411 males) and no history of CVD at baseline were identified. After the identification of the "exposed" patients, of the pool of individuals with no prolactinoma, a total of 10 355 subjects (8557 females and 1798 males) were randomly selected on 1:5 ratio, matching on sex, age, BMI and smoking status.
The study population consisted of a total of 12 588 individuals (10 379 females and 2209 males) with mean age 37.1 (SD 10.2) and 47.3 (SD 14.4) years for females and males, respectively. The baseline characteristics of the subjects of the study are shown in Table 1 .
There was no significant difference in age, smoking status, presence of hypertension or use of lipid-lowering medications between the "exposed" and "nonexposed" cohort at baseline. Although BMI was matched to within 2 Kg/m 2 between the "exposed" and "nonexposed" individuals, this was marginally but statistically different between the two groups for both males and females as a result of the large sample size. Diabetes mellitus was significantly more frequent in the "nonexposed" subjects. The potential impact of these imbalances was further addressed by covariate adjustment analysis.
| Main outcome
During the observation period, the composite CVD outcome was re- Prolactinoma subjects "Nonexposed" subjects Prolactinoma subjects "Nonexposed" subjects 
| Sensitivity and subgroup analyses
Excluding patients with no record of dopamine agonist treatment and their respective controls did not alter the main findings: aIRR was calculated at 1.13 (95% CI: 0.61-2.09, P = .689) for female and 1.98 (95% CI: 1.27-3.09, P = .002) for male patients. A detailed presentation of this analysis is shown in Table 2 . Sensitivity analysis limiting to incident cases and their respective controls revealed similar findings:
aIRR was estimated at 1.04 (95% CI: 0.54-2.03, P = .894) for female patients and 2.00 (95% CI: 1.14-3.49, P = .019) for male patients. A detailed presentation of this analysis is shown in Table 2 
| DISCUSSION
This is the first population-based, retrospective, open-cohort study looking systematically at the cardiovascular morbidity in patients with prolactinoma. We have shown that males have a higher incidence of CVD compared to matched subjects without this diagnosis over a 6-year observation period (IRR 1.72 (95% CI: 1.16-2.55, P = .001)]. In contrast, there is no evidence to suggest an increase in the risk of CVD in female patients with prolactinoma. These findings were also confirmed after adjustment for clinically significant covariates and remained robust in sensitivity analyses. CI, confidence interval; IRR, incidence rate ratio. Statistically significant results are noted in bold.
well as the impact of potential pituitary hormone deficits and/or their management.
In population-based studies, it has been previously shown that the levels of PRL associate positively with inflammatory biomarkers (such as interleukin-6), 23 adverse cardiovascular risk profile 15 and increased cardiovascular mortality. 24 Furthermore, particularly in patients with untreated prolactinoma, a range of metabolic disorders (including insulin resistance, elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B), deranged fibrinolysis (platelet count, fibrinogen, PAI-1 and PAI-1/tissue plasminogen activator ratios), as well as evidence of preclinical atherosclerosis have been reported. [10] [11] [12] [25] [26] [27] [28] Although the duration of hyperprolactinaemia is not known in our cohort of prolactinoma patients, published literature suggests diagnostic delays ranging between 0.5 and 12 years reflecting the minimum period of exposure to high PRL. 1 Whether the impact of previous hyperprolactinaemia on the cardiovascular system is reversible or persists despite treatment with dopamine agonists remains to be elucidated.
Interestingly, we found that the increased risk for CVD in male patients persisted even in the presence of concurrent documented treatment with dopamine agonist; the inclusion of cases with suboptimal biochemical control (due to resistance, intolerance or noncompliance)
cannot be excluded, particularly given that male gender has been independently associated with resistance to cabergoline. 29 It should be also noted that the duration of exposure to high PRL levels may be a significant effect modifier, which is particularly relevant when investigating outcomes like CVD and may provide a possible explanation for the gender differences we identified. In line with this, males are diagnosed at an older age than females, possibly implying longer diagnostic delay and exposure to the consequences of hyperprolactinaemia and of related hypogonadism. 1 Interestingly, a recent retrospective cohort study including approximately 373 individuals with hyperprolactinemia (irrespective of its primary aetiology) reported similar findings with our study. 30 In this report, male hyperprolactinaemic patients had a higher IRR for cardiovascular and all-cause mortality in contrast to female patients, in whom no difference was noted when compared to normoprolactinaemic controls. 30 Of note, an older study of a casecontrol design which explored prolactin levels in those who suffered a coronary artery event and controls did not find higher prolactin levels in the affected patients. 31 This was the case (nonsignificant findings)
in another study of a cohort design, however, the hyperprolactinaemic patients were few 32 and possibly the study was underpowered.
Hypopituitarism is associated with increased cardiovascular mor- The advantages of our study are that it is population-based with large sample size and appropriate matching for confounding factors.
Furthermore, we performed sensitivity analyses, which enhanced the validity of the original results. Limitations include the lack of detailed clinical phenotyping (adenoma size, pituitary dysfunction and its management, response to dopamine agonist treatment, other treatments used for the prolactinoma), which would allow further clarification of the pathogenetic mechanisms of our findings. Moreover, it should be noted that patients with a documented history of CVD event preceding the index date were excluded from the study to ensure outcomes could be attributable to the diagnosis of prolactinoma and not to other pre-existing risk factors of CVD. This may have resulted in a population at low risk for CVD, which may not be reflective of the general population of patients with prolactinoma. Finally, the validity of prolactinomarelated recordings is not fully documented in THIN as yet. Nonetheless, large well-characterized patient registries may facilitate this in the future and will also allow causal interpretation of our observational data.
In conclusion, in a population-based, retrospective cohort study of 12 588 subjects, we have found that incident CVD is increased only in men with prolactinoma. Long-standing hyperprolactinaemia and its consequences, as well as hypopituitarism and its management, may be the underlying mechanisms. The impact of these findings on the longterm mortality of these patients remains to be reviewed.
